Skip to main content
SpringerLink
Log in

Substance Use Disorder and HIV

  • Chapter
  • First Online:
HIV in US Communities of Color

Abstract

The link between HIV and substance use is well established. Substance use and substance use disorder are directly and indirectly related to HIV transmission, delayed diagnosis, entry into care, and worse treatment outcomes. Communities of color are disproportionately affected by negative consequences of HIV and substance use due to structural and societal barriers and risk factors. Treatment for substance use and integration of HIV and substance use treatment lead to improved health outcomes.

With particular attention to race and ethnicity, this chapter discusses the prevalence of drug use in people living with HIV, the link between HIV and substance use, substance use treatment and HIV prevention and treatment, and integration of HIV and substance use treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99–106.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.

    Article  PubMed  Google Scholar 

  3. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.

    Article  CAS  PubMed  Google Scholar 

  4. SAMHSA. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. In: HHS, editor. Rockland: Center for Behavioral Health Statistics and Quality; 2017.

    Google Scholar 

  5. Center for Disease Control and Prevention. HIV surveillance report, 2016; vol. 28. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2017. Accessed 25 Jan 2019.

  6. Vilsaint CL, NeMoyer A, Fillbrunn M, Sadikova E, Kessler RC, Sampson NA, et al. Racial/ethnic differences in 12-month prevalence and persistence of mood, anxiety, and substance use disorders: variation by nativity and socioeconomic status. Compr Psychiatry. 2018;89:52–60.

    Article  PubMed  PubMed Central  Google Scholar 

  7. American Psychiatric Association. Substance-related and addictive disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.

    Chapter  Google Scholar 

  8. O’Brien C. Addiction and dependence in DSM-V. Addiction. 2011;106(5):866–7.

    Article  PubMed  Google Scholar 

  9. Broyles LM, Binswanger IA, Jenkins JA, Finnell DS, Faseru B, Cavaiola A, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus. 2014;35(3):217–21.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Center for Disease Control and Prevention. Behavioral and clinical characteristics of persons with diagnosed HIV infection—medical monitoring project, United State, 2015 cycle (June 2015-May 2016). HIV Surveillance Report 20. 2018.

    Google Scholar 

  11. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.

    Article  CAS  PubMed  Google Scholar 

  12. Durvasula R. HIV/AIDS in older women: unique challenges, unmet needs. Behav Med. 2014;40(3):85–98.

    Article  PubMed  Google Scholar 

  13. Dawson-Rose C, Draughon JE, Zepf R, Cuca YP, Huang E, Freeborn K, et al. Prevalence of substance use in an HIV primary care safety net clinic: a call for screening. J Assoc Nurses AIDS Care. 2017;28(2):238–49.

    Article  PubMed  Google Scholar 

  14. National Institute on Drug Abuse. Drug screening and assessment resources. Chart of evidence-based screening & assessment tools for adults and adolescents. June 2018. Available from: https://www.drugabuse.gov/nidamed-medical-health-professionals/tool-resources-your-practice/additional-screening-resources.

  15. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One. 2009;4(2):e4445.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Center for Disease Control and Prevention. Annual surveillance report of drug-related risks and outcomes—United States, 2017. Surveillance Special Report 1. Center for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2017. Accessed from: https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf.

  17. Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, et al. Trends in any and high-dose opioid analgesic receipt among aging patients with and without HIV. AIDS Behav. 2016;20(3):679–86.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lemons A, DeGroote N, Perez A, Craw J, Nyaku M, Broz D, et al. Opioid misuse among HIV-positive adults in medical care: results from the Medical Monitoring Project, 2009-2014. J Acquir Immune Defic Syndr. 2019;80(2):127–34.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Center for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among persons who inject drugs—National HIV Behavioral Surveillance: Injection Drug Use, 20 U.S.Cities, 2015. HIV Surveillance Special Report 18. 2015.

    Google Scholar 

  20. Friedman SR, Chapman TF, Perlis TE, Rockwell R, Paone D, Sotheran JL, et al. Similarities and differences by race/ethnicity in changes of HIV seroprevalence and related behaviors among drug injectors in New York City, 1991-1996. J Acquir Immune Defic Syndr. 1999;22(1):83–91.

    Article  CAS  PubMed  Google Scholar 

  21. Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Tross S, Perlman D, et al. Racial/ethnic disparities at the end of an HIV epidemic: persons who inject drugs in New York City, 2011-2015. Am J Public Health. 2017;107(7):1157–63.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–27.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Joshi S, Weiser T, Warren-Mears V. Drug, opioid-involved, and heroin-involved overdose deaths among American Indians and Alaska natives - Washington, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(50):1384–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509–19.

    Article  PubMed  Google Scholar 

  25. Center for Disease Control and Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and The U.S. Department of Health and Human Services. Morb Mortal Wkly Rep Recomm Rep. 2012;61:1–43.

    Google Scholar 

  26. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morb Mortal Wkly Rep Recomm Rep. 2006;55(RR-14):1–17; quiz CE1-4.

    Google Scholar 

  27. Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Joseph B, Kerr T, Puskas CM, Montaner J, Wood E, Milloy MJ. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. 2015;27(9):1128–36.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gardner LI, Marks G, Strathdee SA, Loughlin AM, Del Rio C, Kerndt P, et al. Faster entry into HIV care among HIV-infected drug users who had been in drug-use treatment programs. Drug Alcohol Depend. 2016;165:15–21.

    Article  PubMed  Google Scholar 

  31. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. J Int AIDS Soc. 2017;20(1):21585.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145.

    Google Scholar 

  34. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a Cohort Study. Ann Intern Med. 2018;169(3):137–45.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16:1–6.

    Google Scholar 

  37. Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93–103.

    Article  PubMed  CAS  Google Scholar 

  38. Scott-Sheldon LA, Walstrom P, Carey KB, Johnson BT, Carey MP, Team MR. Alcohol use and sexual risk behaviors among individuals infected with HIV: a systematic review and meta-analysis 2012 to early 2013. Curr HIV/AIDS Rep. 2013;10(4):314–23.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bensley KM, McGinnis KA, Fortney J, KCG C, Dombrowski JC, Ornelas I, et al. Patterns of alcohol use among patients living with HIV in urban, large rural, and small rural areas. J Rural Health. 2018;35:330.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Delker E, Brown Q, Hasin DS. Alcohol consumption in demographic subpopulations: An epidemiologic overview. Alcohol Res. 2016;38(1):7–15.

    PubMed  PubMed Central  Google Scholar 

  41. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr. 2009;51(Suppl 1):S13–20.

    Article  PubMed  Google Scholar 

  42. Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Scott-Sheldon LA, Carey KB, Cunningham K, Johnson BT, Carey MP, Team MR. Alcohol use predicts sexual decision-making: a systematic review and meta-analysis of the experimental literature. AIDS Behav. 2016;20(Suppl 1):S19–39.

    Article  PubMed  Google Scholar 

  44. Vagenas P, Ludford KT, Gonzales P, Peinado J, Cabezas C, Gonzales F, et al. Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviors among men who have sex with men in Peru. AIDS Behav. 2014;18(1):120–7.

    Article  PubMed  Google Scholar 

  45. Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP, Team MR. Behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. AIDS Behav. 2017;21(Suppl 2):126–43.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Substance Abuse and Mental Health Services Administration. SAMHSA-HRSA Center for integrated health solutions 2019. Available from: https://www.integration.samhsa.gov/clinical-practice/screening-tools.

  47. Moyer VA, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8.

    PubMed  Google Scholar 

  48. O’Connor EA, Perdue LA, Senger CA, Rushkin M, Patnode CD, Bean SI, et al. Screening and Behavioral Counseling interventions to reduce unhealthy alcohol use in adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(18):1910–28.

    Article  PubMed  Google Scholar 

  49. Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, et al. The American Psychiatric ASsociation practice guidelines for the pharmacologic treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90.

    Article  PubMed  Google Scholar 

  50. SAMHSA-NIAAA. In: SAMHSA, editor. Medication for the treatment of alcohol use disorder: a brief guide. Rockville: HHS Publication; 2015.

    Google Scholar 

  51. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDs. 2007;21(Suppl 1):S68–76.

    Article  PubMed  Google Scholar 

  52. Vu NT, Holt M, Phan HT, Le HT, La LT, Tran GM, et al. Amphetamine-type stimulant use among men who have sex with men (MSM) in Vietnam: results from a socio-ecological, community-based study. Drug Alcohol Depend. 2016;158:110–7.

    Article  PubMed  Google Scholar 

  53. Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet. 2010;376(9739):458–74.

    Article  PubMed  Google Scholar 

  54. Young SD, Shoptaw S. Stimulant use among African American and Latino MSM social networking users. J Addict Dis. 2013;32(1):39–45.

    Article  PubMed  Google Scholar 

  55. Wohl AR, Frye DM, Johnson DF. Demographic characteristics and sexual behaviors associated with methamphetamine use among MSM and non-MSM diagnosed with AIDS in Los Angeles County. AIDS Behav. 2008;12(5):705–12.

    Article  PubMed  Google Scholar 

  56. Halkitis PN, Jerome RC. A comparative analysis of methamphetamine use: black gay and bisexual men in relation to men of other races. Addict Behav. 2008;33(1):83–93.

    Article  PubMed  Google Scholar 

  57. Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS research network of integrated clinical systems cohort. Am J Public Health. 2013;103(8):1457–67.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Mimiaga MJ, Reisner SL, Fontaine YM, Bland SE, Driscoll MA, Isenberg D, et al. Walking the line: stimulant use during sex and HIV risk behavior among Black urban MSM. Drug Alcohol Depend. 2010;110(1–2):30–7.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Cunningham CO, Sohler NL, Berg KM, Shapiro S, Heller D. Type of substance use and access to HIV-related health care. AIDS Patient Care STDs. 2006;20(6):399–407.

    Article  PubMed  Google Scholar 

  60. Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDs. 2002;16(5):233–40.

    Article  PubMed  Google Scholar 

  61. Metsch LR, McCoy HV, McCoy CB, Miles CC, Edlin BR, Pereyra M. Use of health care services by women who use crack cocaine. Women Health. 1999;30(1):35–51.

    Article  CAS  PubMed  Google Scholar 

  62. Metsch LR, Pereyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abus. 2001;13(1–2):155–67.

    Article  CAS  Google Scholar 

  63. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–9.

    Article  PubMed  Google Scholar 

  64. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.

    Article  PubMed  Google Scholar 

  66. Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34(2):161–70.

    Article  PubMed  Google Scholar 

  67. Harada T, Tsutomi H, Mori R, Wilson DB. Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders. Cochrane Database Syst Rev. 2018;12:CD011315.

    PubMed  Google Scholar 

  68. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335–44.

    Article  PubMed  Google Scholar 

  69. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Educ Prev. 2009;21(3 Suppl):28–39.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Pacek LR, Cioe PA. Tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. Curr HIV/AIDS Rep. 2015;12(4):413–20.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d’Arminio Monforte A, et al. Cessation of cigarette smoking and the impact on cancer incidence in HIV-positive persons: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 2018;68:650.

    Article  Google Scholar 

  72. Public Health Service Guideline Update Panel L, Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217–22.

    Google Scholar 

  73. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;3:CD006936.

    Google Scholar 

  74. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med. 2002;346(7):506–12.

    Article  PubMed  Google Scholar 

  75. Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, et al. Smoking cessation, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(11):1430–68.

    Article  Google Scholar 

  76. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Collection: Reports funded by National Institutes of Health. Washington, D.C.; 2017.

    Google Scholar 

  77. Okafor CN, Cook RL, Chen X, Surkan PJ, Becker JT, Shoptaw S, et al. Prevalence and correlates of marijuana use among HIV-seropositive and seronegative men in the Multicenter AIDS Cohort Study (MACS), 1984-2013. Am J Drug Alcohol Abuse. 2017;43(5):556–66.

    Article  PubMed  Google Scholar 

  78. Andrade LF, Carroll KM, Petry NM. Marijuana use is associated with risky sexual behaviors in treatment-seeking polysubstance abusers. Am J Drug Alcohol Abuse. 2013;39(4):266–71.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Morgan E, Skaathun B, Michaels S, Young L, Khanna A, Friedman SR, et al. Marijuana use as a sex-drug is associated with HIV risk among black MSM and their network. AIDS Behav. 2016;20(3):600–7.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy MJ. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63–70.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs. 2004;18(4):215–28.

    Article  PubMed  Google Scholar 

  82. Milloy MJ, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev. 2015;34(2):135–40.

    Article  PubMed  Google Scholar 

  83. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139(4):258–66.

    Article  CAS  PubMed  Google Scholar 

  84. D’Souza G, Matson PA, Grady CD, Nahvi S, Merenstein D, Weber KM, et al. Medicinal and recreational marijuana use among HIV-infected women in the Women’s Interagency HIV Study (WIHS) cohort, 1994-2010. J Acquir Immune Defic Syndr. 2012;61(5):618–26.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol. 2002;42(S1):82S–9S.

    Article  CAS  PubMed  Google Scholar 

  86. Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014;25(1):e1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Slawson G, Milloy MJ, Balneaves L, Simo A, Guillemi S, Hogg R, et al. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2015;19(1):120–7.

    Article  PubMed  PubMed Central  Google Scholar 

  88. de Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38(1):43–6.

    Article  PubMed  Google Scholar 

  89. Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37(1):1–10.

    Article  PubMed  Google Scholar 

  90. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80.

    Article  PubMed  Google Scholar 

  91. Wilson KJ, Doxanakis A, Fairley CK. Predictors for non-adherence to antiretroviral therapy. Sex Health. 2004;1(4):251–7.

    Article  CAS  PubMed  Google Scholar 

  92. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;5:CD005336.

    Google Scholar 

  93. Jhanjee S. Evidence based psychosocial interventions in substance use. Indian J Psychol Med. 2014;36(2):112–8.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320–31.

    Article  CAS  PubMed  Google Scholar 

  95. Penberthy JK, Ait-Daoud N, Vaughan M, Fanning T. Review of treatment for cocaine dependence. Curr Drug Abuse Rev. 2010;3(1):49–62.

    Article  CAS  PubMed  Google Scholar 

  96. Logan DE, Marlatt GA. Harm reduction therapy: a practice-friendly review of research. J Clin Psychol. 2010;66(2):201–14.

    PubMed  PubMed Central  Google Scholar 

  97. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.

    Article  PubMed  Google Scholar 

  98. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–88.

    Article  PubMed  Google Scholar 

  99. Fernandes RM, Cary M, Duarte G, Jesus G, Alarcao J, Torre C, et al. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health. 2017;17(1):309.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Fisher DG, Fenaughty AM, Cagle HH, Wells RS. Needle exchange and injection drug use frequency: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;33(2):199–205.

    Article  PubMed  Google Scholar 

  101. Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.

    Article  PubMed  Google Scholar 

  102. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

    Article  PubMed  Google Scholar 

  103. Netherland J, Hansen H. White opioids: pharmaceutical race and the war on drugs that wasn’t. BioSocieties. 2017;12(2):217–38.

    Article  PubMed  PubMed Central  Google Scholar 

  104. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

    Article  Google Scholar 

  105. Galvan FH, Davis EM, Banks D, Bing EG. HIV stigma and social support among African Americans. AIDS Patient Care STDs. 2008;22(5):423–36.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Birtel MD, Wood L, Kempa NJ. Stigma and social support in substance abuse: implications for mental health and well-being. Psychiatry Res. 2017;252:1–8.

    Article  PubMed  Google Scholar 

  107. Earnshaw VA, Smith LR, Cunningham CO, Copenhaver MM. Intersectionality of internalized HIV stigma and internalized substance use stigma: implications for depressive symptoms. J Health Psychol. 2015;20(8):1083–9.

    Article  PubMed  Google Scholar 

  108. Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367–77.

    Article  PubMed  Google Scholar 

  109. Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S39–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Simeone C, Shapiro B, Lum PJ. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. Addict Sci Clin Pract. 2017;12(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Selwyn PA, Feingold AR, Iezza A, Satyadeo M, Colley J, Torres R, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med. 1989;111(9):761–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

    Deepika Slawek & Chinazo Cunningham

Authors
  1. Deepika Slawek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chinazo Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepika Slawek .

Editor information

Editors and Affiliations

  1. Division of Global Health Equity, Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA

    Bisola O. Ojikutu

  2. Division of General Internal Medicine, Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA

    Valerie E. Stone

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Slawek, D., Cunningham, C. (2021). Substance Use Disorder and HIV. In: Ojikutu, B., Stone, V. (eds) HIV in US Communities of Color. Springer, Cham. https://doi.org/10.1007/978-3-030-48744-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48744-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48743-0

  • Online ISBN: 978-3-030-48744-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation